NASDAQ:PCVX | Free Cash Flow | Vaxcyte, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2018-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$280.63M$2.11M-$282.73M
2025-12-31-$224.83M$2.65M-$227.49M
2025-03-31-$166.27M$5.42M-$171.7M
2024-12-31-$111.4M$4.02M-$115.42M
2024-03-31-$159.12M$5.68M-$164.8M
2023-12-31-$128.81M$5.25M-$134.06M
2023-03-31-$47.69M$5.61M-$53.3M
2022-12-31-$65.22M$1.14M-$66.36M
2022-03-31-$27.7M$2.92M-$30.62M
2021-12-31-$51.09M$1.38M-$52.48M
2021-03-31-$13.21M$1.25M-$14.45M
2020-12-31-$10.77M$722,000.00-$11.49M
2020-03-31-$13.63M$349,000.00-$13.98M
2019-12-31-$14.41M$953,000.00-$15.36M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$655.58M$13.71M-$669.29M
2024-12-31-$452.63M$22.43M-$475.05M
2023-12-31-$296.79M$16.06M-$312.85M
2022-12-31-$170.6M$5.84M-$176.44M
2021-12-31-$121.39M$6.56M-$127.95M
2020-12-31-$46.63M$1.16M-$47.78M
2019-12-31-$47.15M$1.2M-$48.34M
2018-12-31-$30.47M$1.77M-$32.24M